Table 4.
Adjusted clinical outcomes after PSM and IPTW.
| OR (95% CI) |
||
|---|---|---|
| PSM | IPTW | |
| Mortality outcomes | ||
| In hospital mortality | 1.02 (0.62–1.68) | 0.97 (0.59–1.57) |
| Overall mortality | 1.03 (0.63–1.68) | 0.95 (0.59–1.54) |
| Early administration | ||
| In hospital mortality | 0.86 (0.49–1.50) | 0.77 (0.44–1.33) |
| Overall mortality | 0.89 (0.51–1.53) | 0.76 (0.44–1.32) |
| Coefficient (B) [95% CI] |
||
|---|---|---|
| PSM | IPTW | |
| LOS outcomes | ||
| Overall stay | 1.46 [–0.54–3.46] | 1.28 [–0.56–3.15] |
| In hospital stay | 1.19 [–0.10–2.49] | 1.33 [–0.14–2.80] |
| ICU stay | –4.27 [–6.63 to –1.92] | –5.11 [–7.71 to –2.52] |
| Early administration | ||
| Overall stay | 0.14 [–1.93–2.22] | 0.03 [–1.82–1.88] |
| In hospital stay | –0.13 [–1.50–1.24] | 0.14 [–1.32–1.60] |
| ICU stay | –4.56 [–7.14 to –1.98] | –5.23 [–7.87 to –2.59] |
Data obtained using a multivariate logistic regression with tocilizumab as binary variable after PSM and IPTW analysis. Identically, linear variables, such as LOS, were analyzed using multivariable linear regression.
Abbreviations: OR: Odds Ratio. CI: Confidence Interval. PSM: propensity score matching. IPTW: inverse-probability-of-treatment weighting. LOS length of stay.